Endocrine Abstracts

Growth hormone (GH) is secreted throughout life - albeit in diminishing quantities with age. Its many different physiological actions have been known since the classical work of Maurice Raben in the late fifties. However, due to lack of the hormone, replacement therapy was for many years restricted to the pediatric treatment of growth disorder, and its place in medicine became tightly connected with growth, and growth alone. Since the mid eighties natural sequence GH have been...

Aims: To compare the pharmacokinetic and pharmacodynamic profiles of insulin aspart, biphasic insulin aspart 70 (BIAsp70), biphasic insulin aspart 50 (BIAsp50) and soluble human insulin under experimental conditions.Methods: In this randomised, four-period crossover study, 19 type 1 diabetic patients received subcutaneous injections of identical doses (0.2 U/kg) of either insulin aspart, BIAsp70, or BIAsp50 immediately before a standardized meal, or huma...

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...

Aim: Patients with type 2 diabetes (T2DM) have increased risk of cardiovascular disease (CVD) including stroke. The risk of CVD is traditionally assessed using office blood pressure (BP) and lipid profile. Increased arterial stiffness predicts cardiovascular events in the general population. We investigated if arterial stiffness was associated with cerebrovascular disease in patients with T2DM and sex- and age-matched controls indepentl y of classical risk factors.<p class...